Folkman Leaves Behind an Inspiring Legacy of Science, Learning, and Startups

1/16/08

Back when I was starting out in some lowly jobs at the Longwood Medical area, I was constantly reminded of the greatness of certain of the people around me. But one of those people—Judah Folkman—stood out, not only because of his contagious delight and fascination with science, but because of his kindness and unassuming manner.

Folkman, who died yesterday in Denver at the age of 74, was a remarkable human being as well as a brilliant scientist and revered mentor. A surgeon by training, he was a Harvard professor leading the vascular biology program at Boston’s Children’s Hospital at the time of his death.

Folkman’s breakthrough theory about the crucial role of new blood vessel formation (angiogenesis) in cancer growth and spread was one of the most important new biological ideas to emerge in the last 50 years. Today some of top new cancer drugs (including Genentech’s Avastin) are so-called anti-angiogenics that block new blood vessels from forming and thereby deprive tumors of the oxygen and nutrients they need to grow.

The full impact on medicine of Folkman’s angiogenesis research is only beginning to be felt. The Associated Press reported that it has already led to 10 new drugs, helping more than a million patients, and forming the basis of billions of dollars of research worldwide. Angiogenesis turns out to play a critical role in such diverse conditions as arthritis and blindness, in addition to cancer; anti-angiogenics are already being used to treat age-related macular degeneration, one of the most common causes of blindness.

Folkman’s impact was felt locally as well. His work and that of protégés spawned scores of new Boston-area companies and new projects at established companies. MIT’s Robert Langer, for instance, entered Folkman’s lab in 1974 as a chemical engineer highly sought by the likes of oil companies, and emerged as one of Boston biotech’s most prolific inventors and startup founders. In a remembrance of Folkman, Langer writes: “That job changed my life… Dr. Folkman was the greatest role model a young scientist could have. He was a fantastic mentor, a superb role model, one of the nicest human beings I’ve ever met, and a truly great man.”

Most recently, Cambridge-based SynDexRx was formed in 2007 around a broad patent portfolio developed in Folkman’s lab; the company’s lead drug candidate is an anti-angiogenic called Caplostatin. SynDexRx’s just announced, eye-popping advisory board, includes oncology heavies Rakesh K. Jain, Daniel Von Hoff, and Roy Herbst—a testament to Folkman’s influence on his peers.

Naturally, Folkman’s theory about angiogenesis didn’t catch on immediately, but he championed it tirelessly and with remarkably good humor. Even during the inevitable “backlash stage,” when critics were pointing to early anti-angiogenic drugs that were not showing much effect, he was unperturbed. He had clearly anticipated rough spots. But his optimism was fueled by both a firm conviction in his science and a determination to help patients.

In a talk he gave in 2005, for instance, Folkman described how he had gathered a list of already approved drugs that were now also known to be anti-angiogenics, and was trying to give terminal cancer patients a last chance by helping them get access to those therapies.

The last time I saw Folkman it was on the Amtrak from DC to Boston about two years ago. Recognizing him immediately, I boldly put my hand out and said “Dr. Folkman, do you remember me?” (The circumstances of our previous meetings had been entirely forgettable of course.) He greeted me with his typical warmth, inquiring about my work, and then we were quickly talking about science.

“Next time you’re in the neighborhood, you must come to the lab,” he said with characteristic glee. “We’re doing some really amazing things.”

That was Judah Folkman.

By posting a comment, you agree to our terms and conditions.

  • http://www.xconomy.com/author/dresnick/ David Resnick

    Thank you for your article. Dr. Folkman was an amazing man. Not only was he a brilliant scientist, he was a caring person. The moment you describe meeting him on the train and that special feeling he gave you, was one of his many gifts. I was fortunate that my career as a patent attorney started 1989 working with Dr. Folkman and his lab at Children’s. I was certainly spoiled getting to sit with Dr. Folkman and chatting about science. It was a science nerd’s dream job. I was also fortunate that I was able to continue to work with him and witness an almost 20 years slice of his remarkable career. He ignored convention. He was persistent. He cared about his family, friends and patients. His legacy is in the 100s of people he trained in the vascular biology program at Children’s. They each carry a little of Dr. Folkman and will continue his mission of making this world a little better for all of us.

  • Malorye Allison

    What a wonderful way to get your start in the field! Many people have connected with me about this article to tell me their own great stories. If you want to show someone “classic Folkman” in action send them to the ASCO Website for the Webcast of his 2005 Presidential Address. It was fascinating, and fun of course. The title is: “Angiogenesis-based biomarkers: Can cancer be treated before it can anatomically be located?” The link is kind of long, but you can find the Webcast easily by Googling it.

  • http://daley.med.harvard.edu/assets/Willy/willy.htm Willy Lensch

    Judah Folkman was such a great guy. All of his scientific and medical accolades and honors aside, he was a person who would sit with you and tell you the best stories. What a wonderful teacher he was.